🏛️ Verified NIH Record • Updated 2026-01-20
A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer (NCT03873402)
A Phase 3b, Randomized, Double-blind Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Monotherapy for Patients With Previously Untreated Advanced Renal Cell Carcinoma and Intermediate- or Poor-Risk Factors
🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Bristol-Myers Squibb
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to test the effectiveness and safety of nivolumab combined with ipilimumab compared to nivolumab monotherapy in participants with previously untreated kidney cancer that has spread.
Who can join: Review the eligibility criteria below.
Location: Local Institution - 0013 — Washington D.C., District of Columbia
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (78 Sites)
Showing the first 25 of 78 sites.
- Local Institution - 0013 — Washington D.C., District of Columbia
- Local Institution - 0053 — Athens, Georgia
- Local Institution - 0066 — Boston, Massachusetts
- Local Institution - 0088 — Boston, Massachusetts
- Local Institution - 0086 — Boston, Massachusetts
- The Reading Hosp Med Ctr Reg Cancer Ctr — West Reading, Pennsylvania
- Local Institution - 0084 — Charleston, South Carolina
- Local Institution - 0100 — Capital Federal, Buenos Aires
- Local Institution - 0011 — Ciudad Autónoma de Buenos Aires, Buenos Aires
- Local Institution - 0060 — Mar del Plata, Buenos Aires
- Local Institution - 0025 — Río Cuarto, Córdoba Province
- Local Institution - 0001 — Viedma, Río Negro Province
- Local Institution - 0005 — Córdoba,
- Local Institution - 0002 — San Juan,
- Local Institution - 0033 — Graz,
- Local Institution - 0031 — Vienna,
- Local Institution - 0032 — Wels,
- Local Institution - 0017 — Independencia, Santiago Metropolitan
- Local Institution - 0003 — Santiago, Santiago Metropolitan
- Local Institution - 0034 — Santiago, Santiago Metropolitan
- Local Institution - 0004 — Viña del Mar, Valparaiso
- Local Institution - 0012 — Viña El Mar, Valparaiso
- Local Institution - 0020 — Brno, South Moravian
- Local Institution - 0097 — Brno,
- Local Institution - 0019 — Prague,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Renal Cell Carcinoma
- A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma — Birmingham, Alabama
- 89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma — Dallas, Texas
- Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma — Stanford, California
- Follow-up After Metastasectomy in Patients With Kidney Cancer — Houston, Texas
- Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma — La Jolla, California
- A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors — Los Angeles, California
Explore by condition: All Renal Cell Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.